Cutera : Announces Fourth Quarter and Full-Year 2021 Financial Results along with 2022 Outlook - Form 8-K
February 22, 2022 at 04:31 pm EST
Share
Cutera, Inc. Announces Fourth Quarter and Full-Year 2021 Financial Results along with 2022 Outlook
Achieved Record Revenue in Fourth Quarter and Full-Year 2021
BRISBANE, California, February 22, 2022 ─ Cutera, Inc. (NASDAQ: CUTR) ("Cutera" or the "Company"), a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide, today reported financial results for the fourth quarter and full-year ended December 31, 2021.
Fourth Quarter 2021 Financial and Operational Highlights
•Revenue was $65.6 million, an increase of 31% from the prior-year period, driven by strong performance across the business, with particular strength in North American Capital Equipment;
◦Capital Equipment revenue of $43.6 million increased 44% over the prior-year period;
◦Recurring revenue, defined as the combination of Skincare, Consumable Products, and Service, was $22.1 million, an increase of 12% over the prior-year period;
▪Skincare revenue of $10.7 million increased 2% over the prior-year period, impacted by 3Q21 pre-buying in advance of the planned price increase;
▪Consumable Product revenue of $5.4 million grew 77% over prior-year period; and
▪Service revenue of $6.0 million decreased 4% over the prior-year period;
•Gross Margin was 58.2%, compared to 56.2% in the prior-year period, driven by better sales mix and continued leverage, partially offset by modest inflationary pressures;
•Operating Expenses were $40.2 million in the quarter, as compared to $26.6 million in the prior-year period, driven by variable costs from increased sales and by investments in our Acne program;
•Net loss was $3.9 million, or ($0.22) per fully diluted share, compared to a net income of $2.2 million, or $0.12 per fully diluted share, in the prior-year period; and
•Adjusted EBITDA was $4.3 million in the period as compared to $4.7 million in the prior-year period. Excluding Acne program spend of $4.6 million in the quarter, our adjusted EBITDA would have been $8.9 million.
Full-Year 2021 Financial and Operational Highlights
•Revenue was $231.3 million, an increase of 57% from the prior-year period;
◦Capital Equipment revenue of $139.6 million increased 54% over the prior-year period;
◦Recurring revenue, defined as the combination of Skincare, Consumable Products, and Service, was $91.6 million, an increase of 61% over the prior-year period;
▪Skincare revenue of $49.7 million increased 98% over the prior-year period;
▪Consumable Product revenue of $16.4 million increased 77% over the prior-year period; and
▪Service revenue of $25.6 million increased 13% over the prior-year period;
•Gross Margin was 57.6%, compared to 51.3% in the prior-year period;
•Operating Expenses were $131.3 million, as compared to $98.6 million in the prior-year period;
•Net Income was $2.1 million, or $0.11 per fully diluted share, compared to a net loss of $23.9 million, or ($1.43) per fully diluted share, a year ago; and
•Adjusted EBITDA was $20.7 million as compared to a loss of $4.8 million a year ago. Excluding full-year Acne program spend of $9.5 million, our adjusted EBITDA would have been $30.2 million, a seven-fold improvement.
"I am pleased with our strong fourth-quarter performance, which was driven by our team's outstanding commercial execution and supported by robust underlying patient demand. I am particularly encouraged that our North American Capital business eclipsed Pre-Covid levels and delivered 56% growth in the quarter" commented Dave Mowry, Chief Executive Officer of Cutera, Inc. "We anticipate that this top-line momentum will continue as we move through the year, driven by our growing capital equipment pipeline and the strong ongoing patient demand. In light of our business strength, in combination with future product launches, we are tremendously excited for the year ahead."
2022 Outlook
The Company expects full-year 2022 constant currency revenue in the range of $255 million to $260 million, based on our current product portfolio. For the sake of clarity, this guidance does not include any revenue from our Acne device program.
Conference Call
The Company's management will host a conference call to discuss these results and related matters today at 1:30 p.m. PT (4:30 p.m. ET). Participating on the call will be Dave Mowry, Chief Executive Officer and Rohan Seth, Chief Financial Officer.
To participate in the conference call, dial 1-877-705-6003 (domestic) or + 1-201-493-6725 (international) and refer to the Conference Code: 13726648.
The call will also be webcast and can be accessed from the Investor Relations section of Cutera's website at http://www.cutera.com/. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.
About Cutera, Inc.
Brisbane, California-based Cutera is a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide. Since 1998, Cutera has developed innovative, easy-to-use products that enable physicians and other qualified practitioners to offer safe and effective aesthetic treatments to their patients. For more information, call 1-888-4CUTERA or visit www.cutera.com.
*Use of Non-GAAP Financial Measures
In this press release, in order to supplement the Company's condensed consolidated financial statements presented in accordance with Generally Accepted Accounting Principles, or GAAP, management has disclosed certain non-GAAP financial measures for the statement of operations and net income (loss) per diluted share. Non-GAAP adjustments include stock-based compensation, depreciation, amortization, executive and other non-recurring separation costs, customer relationship management ("CRM") and enterprise resource planning ("ERP") system costs, non-recurring legal and litigation costs, as well as the net tax impact of excluding these items. From time to time in the future, there may be other items that we may exclude if the Company believes that doing so is consistent with the goal of providing useful information to investors and management. The Company has provided a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure. The Company has not provided a reconciliation of non-GAAP guidance measures to the corresponding GAAP measures on a forward-looking basis due to the potential significant variability, limited visibility, unpredictability, or unique non-recurring nature of the items. Forward-looking non-GAAP measures include adjusted EBITDA. The Company defines adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, stock-based compensation, executive and other non-recurring separation costs, customer relationship management and enterprise resource planning system costs, and non-recurring legal and litigation costs.
Company management uses these measurements as aids in monitoring the Company's ongoing financial performance from quarter to quarter, and year to year, on a regular basis and for benchmarking against other similar companies. Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP financial measures should be considered along with, but not as alternatives to, the operating performance measure as prescribed by GAAP. Non-GAAP financial measures for the statement of operations and net income per diluted share exclude the following:
Non-cash expenses for stock-based compensation. The Company has excluded the effect of stock-based compensation expenses in calculating its non-GAAP operating expenses and net income measures. Although stock-based compensation is a key incentive offered to the Company's employees, the Company continues to evaluate its business performance excluding stock-based compensation expenses. The Company records stock-based compensation expense related to grants of options, employee stock purchase plan, and performance and restricted stock. Depending upon the size, timing and the terms of the grants, this expense may vary significantly but will recur in future periods. The Company believes that excluding stock-based compensation better allows for comparisons to its peer companies;
Depreciation and amortization. The Company has excluded depreciation and amortization expense in calculating its non-GAAP operating expenses and net income measures. Depreciation and amortization are non-cash charges to current operations;
Executive and other non-recurring separation costs. We have excluded costs associated with the resignation of our former Executive Officers in calculating our non-GAAP operating expenses and net income measures. We exclude these and other non-recurring employee separation costs because we believe that these items do not reflect future operating expenses;
Customer Relationship Management. We have excluded CRM system costs related to direct and incremental costs incurred in connection with our multi-phase implementation of a new CRM solution and the related technology infrastructure costs. We exclude these costs because we believe that these items do not reflect future operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of our operating performance;
Enterprise Resource Planning. We have excluded ERP system costs related to direct and incremental costs incurred in connection with our multi-phase implementation of a new ERP solution and the related technology infrastructure costs. We exclude these costs because we believe that these items do not reflect future operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of our operating performance; and
Non-recurring legal and litigation costs. We have excluded costs incurred related to third party litigation and disputes, that are of a non-recurring nature.
The Company believes that excluding all of the items above allows users of its financial statements to better review and assess both current and historical results of operations.
Safe Harbor Statement
Certain statements in this press release, other than purely historical information, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These statements include, but are not limited to, Cutera's plans, objectives, strategies, financial performance and outlook, product launches and performance, trends, prospects or future events and involve known and unknown risks that are difficult to predict. As a result, the Company's actual financial results, performance, achievements or prospects may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may,""could,""seek,""guidance,""predict,""potential,""likely,""believe,""will,""should,""expect,""anticipate,""estimate,""plan,""intend,""forecast,""foresee" or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Cutera's actual results to differ materially from the statements contained herein. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements. There are a number of risks, uncertainties and other important factors, many of which are beyond the Company's control, that could cause its actual results to differ materially from the forward-looking statements contained in this press release, including those described in the "Risk Factors" section of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, the Registration Statement on Form S-,8 and other documents filed from time to time with the United States Securities and Exchange Commission by Cutera.
All information in this press release is as of the date of its release. Accordingly, undue reliance should not be placed on forward-looking statements. Cutera undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. If the Company updates one or more forward-looking statements, no inference should be drawn that it will make additional updates with respect to those or other forward-looking statements. Cutera's financial performance for the fourth quarter and full year ended December 31, 2021, as discussed in this release, is preliminary and unaudited, and subject to adjustment.
Cutera, Inc.
Anne Werdan
Director, Corporate Communications
415-657-5500
awerdan@cutera.com
CUTERA, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)
December 31,
2021
December 31,
2020
Assets
Current assets:
Cash and cash equivalents
$
164,164
$
47,047
Accounts receivable, net
31,449
21,962
Inventories
39,503
28,508
Other current assets and prepaid expenses
14,545
8,779
Total current assets
249,661
106,296
Property and equipment, net
3,019
2,299
Deferred tax asset
778
643
Operating lease right-of-use assets
14,627
17,076
Goodwill
1,339
1,339
Other long-term assets
10,169
5,080
Restricted cash
700
-
Total assets
$
280,293
$
132,733
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable
$
7,891
$
6,684
Accrued liabilities
54,100
32,295
Operating leases liabilities
2,419
2,260
PPP loan payable
-
3,630
Deferred revenue
9,490
9,489
Total current liabilities
73,900
54,358
Deferred revenue, net of current portion
1,335
1,748
Operating lease liabilities, net of current portion
13,483
15,950
PPP loan payable, net of current portion
-
3,555
Convertible notes, net of unamortized debt issuance costs
134,243
-
Other long-term liabilities
763
242
Total liabilities
223,724
75,853
Stockholders' equity:
Common stock
18
18
Additional paid-in capital
114,724
117,097
Accumulated deficit
(58,173)
(60,235)
Total stockholders' equity
56,569
56,880
Total liabilities and stockholders' equity
$
280,293
$
132,733
CUTERA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)
Three Months Ended
Twelve Months Ended
December 31,
2021
December 31,
2020
December 31,
2021
December 31,
2020
Products
$
59,647
$
43,723
$
205,703
$
125,113
Service
5,982
6,220
25,567
22,570
Total net revenue
65,629
49,943
231,270
147,683
Products
23,565
17,999
83,048
58,325
Service
3,883
3,878
15,117
13,586
Total cost of revenue
27,448
21,877
98,165
71,911
Gross profit
38,181
28,066
133,105
75,772
Gross margin %
58.2
%
56.2
%
57.6
%
51.3
%
Operating expenses:
Sales and marketing
24,094
14,656
76,762
52,766
Research and development
6,804
4,029
21,568
14,322
General and administrative
9,312
7,938
32,945
31,512
Total operating expenses
40,210
26,623
131,275
98,600
Income (loss) from operations
(2,029)
1,443
1,830
(22,828)
Interest and other income (expense), net
Amortization of debt issuance costs
(218)
-
(710)
-
Interest on convertible notes
(777)
-
(2,514)
-
Gain on extinguishment of PPP loan
-
-
7,185
-
Other income (expense), net
(430)
7
(2,406)
(579)
Income (loss) before income taxes
(3,454)
1,450
3,385
(23,407)
Income tax expense (benefit)
481
(738)
1,323
470
Net income (loss)
$
(3,935)
$
2,188
$
2,062
$
(23,877)
Net income (loss) per share:
Basic
$
(0.22)
$
0.12
$
0.12
$
(1.43)
Diluted
$
(0.22)
$
0.12
$
0.11
$
(1.43)
Weighted-average number of shares used in per share calculations:
Basic
17,980
17,653
17,891
16,691
Diluted
17,980
17,840
18,362
16,691
CUTERA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
Three Months Ended
Twelve Months Ended
December 31, 2021
December 31, 2020
December 31, 2021
December 31, 2020
Cash flows from operating activities:
Net income (loss)
$
(3,935)
$
2,188
$
2,062
$
(23,877)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Stock-based compensation
4,665
2,052
13,172
10,109
Depreciation and amortization
330
338
1,344
1,394
Amortization of contract acquisition costs
427
579
1,857
2,593
Amortization of debt issuance costs
218
-
710
-
Impairment of capitalized cloud computing costs
-
-
182
805
Change in deferred tax asset
(189)
(143)
(135)
(220)
Provision for credit losses
(14)
394
87
2,144
Gain on extinguishment of PPP loan
-
-
(7,185)
-
Change in right-of-use asset
611
705
2,292
2,522
Other
46
183
1
513
Changes in assets and liabilities:
Accounts receivable
(675)
(4,759)
(9,574)
(2,550)
Inventories
(4,010)
825
(10,936)
5,413
Other current assets and prepaid expenses
(1,195)
(1,891)
(5,766)
(3,164)
Other long-term assets
(3,641)
(366)
(7,128)
(2,067)
Accounts payable
632
(148)
1,207
(6,034)
Accrued liabilities
9,826
5,169
21,608
161
Operating lease liabilities
(578)
-
(2,151)
(1,598)
Deferred revenue
145
(587)
(412)
(2,985)
Income tax liability
-
(93)
-
(93)
Net cash provided by (used in) operating
2,663
4,446
1,235
(16,934)
Cash flows from investing activities:
Acquisition of property, equipment and software
(633)
(505)
(1,015)
(1,279)
Disposal of property and equipment
-
30
71
30
Proceeds from sales of marketable investments
-
5,648
-
5,648
Proceeds from maturities of marketable investments
-
9,050
-
28,050
Purchase of marketable investments
-
(1,649)
-
(26,060)
Net cash provided by (used in) investing activities
(633)
12,574
(944)
6,389
Cash flows from financing activities:
Proceeds from exercise of stock options and employee stock purchase plan
709
723
2,765
1,579
Proceeds from PPP loan
-
-
-
7,167
Gross proceeds from equity offering
-
-
-
28,798
Issuance costs on the public offering
-
-
-
(2,303)
Purchase of capped call
-
-
(16,134)
-
Proceeds from issuance of convertible notes
-
-
138,250
-
Payment of issuance costs of convertible notes
-
-
(4,717)
-
Taxes paid related to net share settlement of equity awards
(213)
(88)
(2,176)
(3,428)
Payments on finance lease obligations
(148)
(2)
(462)
(537)
Net cash provided by financing activities
348
633
117,526
31,276
Net increase in cash, cash equivalents and restricted cash
2,378
17,653
117,817
20,731
Cash, cash equivalents, and restricted cash at beginning of period
162,486
29,394
47,047
26,316
Cash, cash equivalents, and restricted cash at end of period
$
164,864
$
47,047
$
164,864
$
47,047
CUTERA, INC.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in thousands, except percentage data)
(unaudited)
Three Months Ended
% Change
Twelve Months Ended
% Change
December 31, 2021
December 31, 2021
2021 Vs
2020
December 31, 2021
December 31, 2021
2021 Vs
2020
Revenue By Geography:
North America
$
35,827
$
23,966
+49.5
%
$
111,621
$
69,455
+60.7
%
Japan
16,924
16,089
+5.2
%
70,235
43,265
+62.3
%
Rest of World
12,878
9,888
+30.2
%
49,414
34,963
+41.3
%
Total Net Revenue
$
65,629
$
49,943
+31.4
%
$
231,270
$
147,683
+56.6
%
Rest of World (including Japan) as a percentage of total revenue
45.4
%
52.0
%
51.7
%
53.0
%
Revenue By Product Category:
Systems
-North America
$
28,747
$
18,426
+56.0
%
$
86,100
$
50,721
+69.8
%
-Rest of World (including Japan)
14,807
11,719
+26.4
%
53,533
40,045
+33.7
%
Total Systems
43,554
30,145
+44.5
%
139,633
90,766
+53.8
%
Consumables
5,361
3,023
+77.3
%
16,401
9,286
+76.6
%
Skincare
10,732
10,555
+1.7
%
49,669
25,061
+98.2
%
Total Products
59,647
43,723
+36.4
%
205,703
125,113
+64.4
%
Service
5,982
6,220
(3.8)
%
25,567
22,570
+13.3
%
Total Net Revenue
$
65,629
$
49,943
+31.4
%
$
231,270
$
147,683
+56.6
%
Three Months Ended
Twelve Months Ended
December 31, 2021
December 31, 2020
December 31, 2021
December 31, 2020
Pre-tax Stock-Based Compensation Expense:
Cost of revenue
$
500
$
306
$
1,408
$
1,665
Sales and marketing
1,206
767
3,160
3,384
Research and development
1,156
325
2,784
1,670
General and administrative
1,803
654
5,820
3,390
$
4,665
$
2,052
$
13,172
$
10,109
CUTERA, INC.
RECONCILIATION OF GAAP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
TO NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)
Three Months Ended December 31, 2021
GAAP
Depreciation
and
Amortization
Stock-Based
Compensation
CRM and ERP Implementation Cost
Severance (RIF)
Legal - Lutronic
Other Adjustments
Non-GAAP
Net revenue
$
65,629
-
-
-
-
-
-
$
65,629
Cost of revenue
27,448
(94)
(500)
-
-
-
-
26,854
Gross profit
38,181
94
500
-
-
-
-
38,775
Gross margin %
58.2
%
59.1
%
Operating expenses:
Sales and marketing
24,094
(593)
(1,206)
-
-
-
-
22,295
Research and development
6,804
(49)
(1,156)
-
-
-
-
5,599
General and administrative
9,312
(4)
(1,803)
(711)
-
(222)
-
6,572
Total operating expenses
40,210
40210
(646)
(4,165)
(711)
-
(222)
-
34,466
Income (loss) from operations
(2,029)
740
4,665
711
-
222
-
4,309
Interest and other income (expense), net
Amortization of debt issuance costs
(218)
-
-
-
-
-
-
(218)
Interest on convertible notes
(777)
-
-
-
-
-
-
(777)
Other expense
(430)
-
-
-
-
-
-
(430)
Total interest and other income (expense), net
(1,425)
-
-
-
-
-
-
(1,425)
Income (loss) before income taxes
(3,454)
740
4,665
711
-
222
-
2,884
Income tax expense
481
-
-
-
-
-
-
481
Net income (loss)
$
(3,935)
$
740
$
4,665
$
711
$
-
$
222
$
-
$
2,403
Net income (loss) per share:
Basic
$
(0.22)
$
0.13
Weighted-average number of shares used in per share calculations:
Basic
17,980
17,980
Operating expenses as a % of net revenue
GAAP
Non-GAAP
Sales and marketing
36.7
%
34.0
%
Research and development
10.4
%
8.5
%
General and administrative
14.2
%
10.0
%
61.3
%
52.5
%
CUTERA, INC.
RECONCILIATION OF GAAP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
TO NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)
Three Months Ended December 31, 2020
GAAP
Depreciation
and
Amortization
Stock-Based
Compensation
CRM and ERP
Implementation/
write-off
Severance (RIF)
Legal - Former CFO Settlement/Lutronic
Other Adjustments
Non-GAAP
Net revenue
$
49,943
-
-
-
-
-
-
$
49,943
Cost of revenue
21,877
(174)
(306)
-
-
-
275
21,672
Gross profit
28,066
174
306
-
-
-
(275)
28,271
Gross margin %
56.2
%
56.6
%
Operating expenses:
Sales and marketing
14,656
(682)
(767)
-
-
-
-
13,207
Research and development
4,029
(34)
(325)
-
-
-
-
3,670
General and administrative
7,938
(27)
(654)
-
-
(566)
-
6,691
Total operating expenses
26,623
(743)
(1,746)
-
-
(566)
-
23,568
Income (loss) from operations
1,443
917
2,052
-
-
566
(275)
4,703
Interest and other income, net
7
-
0
-
-
-
-
-
7
Income (loss) before income taxes
1,450
917
2,052
-
-
566
(275)
4,710
Income tax expense
(738)
-
-
-
-
-
-
(738)
Net income (loss)
$
2,188
$
917
$
2,052
$
-
$
-
$
566
$
(275)
$
5,448
Net income (loss) per share:
Basic
$
0.12
$
0.31
Weighted-average number of shares used in per share calculations:
Basic
17,653
17,653
Operating expenses as a % of net revenue
GAAP
Non-GAAP
Sales and marketing
29.3
%
26.4
%
Research and development
8.1
%
7.3
%
General and administrative
15.9
%
13.4
%
53.3
%
47.1
%
CUTERA, INC.
RECONCILIATION OF GAAP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
TO NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)
Twelve Months Ended December 31 , 2021
GAAP
Depreciation
and
Amortization
Stock-Based
Compensation
CRM and ERP Implementation Cost
Severance (RIF)
Legal - Lutronic
Other Adjustments
Non-GAAP
Net revenue
$
231,270
-
-
-
-
-
-
$
231,270
Cost of revenue
98,165
(526)
(1,408)
-
-
-
791
97,022
Gross profit
133,105
526
1,408
-
-
-
(791)
134,248
Gross margin %
57.6
%
58.0
%
Operating expenses:
Sales and marketing
76,762
(2,420)
(3,160)
(182)
(638)
-
-
70,362
Research and development
21,568
(182)
(2,784)
-
-
-
-
18,602
General and administrative
32,945
(60)
(5,820)
(1,316)
-
(1,201)
-
24,548
Total operating expenses
131,275
131275
(2,662)
(11,764)
(1,498)
(638)
(1,201)
-
113,512
Income (loss) from operations
1,830
3,188
13,172
1,498
638
1,201
(791)
20,736
Interest and other income (expense), net
Amortization of debt issuance costs
(710)
-
-
-
-
-
-
(710)
Interest on convertible notes
(2,514)
-
-
-
-
-
-
(2,514)
Gain on extinguishment of PPP loan
7,185
-
-
-
-
-
(7,185)
-
Other expense
(2,406)
-
-
-
-
-
-
(2,406)
Total interest and other income (expense), net
1,555
-
-
-
-
-
(7,185)
(5,630)
Income (loss) before income taxes
3,385
3,188
13,172
1,498
638
1,201
(7,976)
15,106
Income tax expense
1,323
-
-
-
-
-
-
1,323
Net income (loss)
$
2,062
$
3,188
$
13,172
$
1,498
$
638
$
1,201
$
(7,976)
$
13,783
Net income (loss) per share:
Basic
$
0.12
$
0.77
Weighted-average number of shares used in per share calculations:
Basic
17,891
17,891
Operating expenses as a % of net revenue
GAAP
Non-GAAP
Sales and marketing
33.2
%
30.4
%
Research and development
9.3
%
8.0
%
General and administrative
14.2
%
10.6
%
56.7
%
49.0
%
CUTERA, INC.
RECONCILIATION OF GAAP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
TO NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)
Twelve Months Ended December 31, 2020
GAAP
Depreciation
and
Amortization
Stock-Based
Compensation
CRM and ERP
Implementation/
write-off
Severance (RIF)
Legal/Former CFO Settlement/Lutronic
Other Adjustments
Non-GAAP
Net revenue
$
147,683
-
-
-
-
-
-
$
147,683
Cost of revenue
71,911
(591)
(1,665)
-
(318)
-
275
69,612
Gross profit
75,772
591
1,665
-
318
-
(275)
78,071
Gross margin %
51.3
%
52.9
%
Operating expenses:
Sales and marketing
52,766
(3,136)
(3,384)
-
(274)
-
-
45,972
Research and development
14,322
(149)
(1,670)
-
(130)
-
-
12,373
General and administrative
31,512
(111)
(3,390)
(1,139)
(101)
(1,925)
(324)
24,522
Total operating expenses
98,600
(3,396)
(8,444)
(1,139)
(505)
(1,925)
(324)
82,867
Income (loss) from operations
(22,828)
3,987
10,109
1,139
823
1,925
49
(4,796)
Interest and other expense, net
(579)
-
-
-
-
-
-
(579)
Income (loss) before income taxes
(23,407)
3,987
10,109
1,139
823
1,925
49
(5,375)
Income tax expense
470
-
-
-
-
-
9
479
Net income (loss)
$
(23,877)
$
3,987
$
10,109
$
1,139
$
823
$
1,925
$
40
$
(5,854)
Net income (loss) per share:
Basic
$
(1.43)
$
(0.35)
Weighted-average number of shares used in per share calculations:
Basic
16,691
16,691
Operating expenses as a % of net revenue
GAAP
Non-GAAP
Sales and marketing
35.7
%
31.1
%
Research and development
9.7
%
8.4
%
General and administrative
21.3
%
16.6
%
66.7
%
56.1
%
CUTERA, INC.
RECONCILIATION OF LOSS TO ADJUSTED EBITDA
(in thousands)
(unaudited)
Three Months
Ended
Twelve Months Ended
December 31, 2021
Net Income
$
(3,935)
$
2,062
Adjustments:
Stock-based compensation
4,665
13,172
Depreciation and amortization
740
3,188
ERP implementation cost
711
1,498
Severance
-
638
Legal - Lutronic
222
1,201
Other adjustments
-
(791)
Gain on extinguishment of PPP loan
-
(7,185)
Other expense
1,425
5,630
Income tax expense
481
1,323
Total adjustments
8,244
18,674
Adjusted EBITDA
$
4,309
$
20,736
Attachments
Original Link
Original Document
Permalink
Disclaimer
Cutera Inc. published this content on 22 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 February 2022 21:28:52 UTC.
Cutera, Inc. develops, manufactures, distributes, and markets energy-based product platforms for medical practitioners, enabling them to offer treatments to their customers. The Company distributes third-party manufactured skincare products and secret systems and consumables. Its system platforms include AviClear, enlighten, excel, truSculpt, Secret PRO, Secret RF, and xeo. The Companyâs Cutera Core segment consists of the Companyâs systems, consumables, skincare, and service businesses. The Cutera Core segment develops, distributes and manufactures energy-based systems for medical practitioners in addition to distributing third-party manufactured skincare products in Japan. The Companyâs AviClear segment consists of the AviClear business. The Companyâs acne solution, AviClear, is a prescription-free, drug-free laser treatment for the treatment of mild to severe acne. Its products include CUTERA, ACUTIP 500, AVITM, AVI360, AVIANALYTICSTM, AVICARE COOLGLIDE, and more.